Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
INVAGESIC FORTE vs ANEXSIA 7.5/650
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of an opioid agonist (codeine) and a non-opioid analgesic (ibuprofen). Codeine is metabolized to morphine, which binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Ibuprofen inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby decreasing inflammation and pain.
Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception; acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and fever.
Management of mild to moderate pain,Off-label: acute pain, dental pain, postoperative pain
Management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
One tablet (hydrocodone bitartrate 10 mg / acetaminophen 300 mg / ibuprofen 200 mg) orally every 4 to 6 hours as needed for pain; maximum 5 tablets per day.
1 tablet orally every 4 to 6 hours as needed; maximum 6 tablets per day.
Terminal half-life: 2-3 hours (prolonged in renal impairment; clinical context: requires dosing interval adjustment in Cr Cl <30 m L/min)
Hydrocodone: Terminal half-life 3.8-7.2 hours (mean 5.6 h). Acetaminophen: 1.5-2.5 hours (therapeutic) but prolonged to >4 hours in overdose with hepatotoxicity risk.
Codeine is metabolized via CYP2D6 to morphine, and via CYP3A4 to norcodeine. Ibuprofen is metabolized primarily via CYP2C9.
Hydrocodone: CYP3A4 and CYP2D6; acetaminophen: primarily liver glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3), with minor CYP2E1 oxidation.
Renal: 90% (70% unchanged, 20% as glucuronide conjugate); Fecal/biliary: <5%
Hydrocodone: Renal elimination of metabolites (hydromorphone, norhydrocodone) and unchanged drug accounts for ~60-90% of clearance. Acetaminophen: ~85% of dose is excreted in urine as glucuronide and sulfate conjugates; 5-10% unchanged; 2-5% as mercapturate.
99% (primarily albumin; binding reduced in hypoalbuminemia, uremia, and neonates)
Hydrocodone: ~36% bound to serum proteins. Acetaminophen: 10-25% bound (minimal binding).
0.1-0.2 L/kg (clinical meaning: low Vd indicates limited extravascular distribution, consistent with high protein binding and acidic drug nature)
Hydrocodone: Vd ~3-5 L/kg (wide distribution). Acetaminophen: Vd ~0.9-1.0 L/kg (primarily body water).
Oral: 80-100% (food delays absorption but does not reduce extent)
Oral: Hydrocodone ~70-80% (variable first-pass). Acetaminophen ~63-89% (mean 75-80%).
Contraindicated in severe renal impairment (e GFR < 30 m L/min/1.73 m²). For moderate impairment (e GFR 30-59 m L/min/1.73 m²): use lowest effective dose, maximum 4 tablets per day; avoid in dialysis.
Cr Cl <30 m L/min: contraindicated; Cr Cl 30-60 m L/min: maximum 3 tablets per day; given the hydrocodone component, avoid in severe renal impairment.
Contraindicated in Child-Pugh class C (severe hepatic impairment). For class B (moderate): reduce dose by 50% and monitor; do not exceed 4 tablets per day. Class A (mild): no adjustment but caution.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50% and monitor; Child-Pugh Class C: contraindicated due to hydrocodone.
Not recommended for pediatric patients under 18 years of age due to risk of serious adverse effects.
Not recommended in pediatric patients due to risk of respiratory depression; for ages <18, contraindicated.
Start at lower end of dosing range (e.g., 1 tablet every 6 hours); maximum 4 tablets per day. Avoid in patients with creatinine clearance < 30 m L/min. Monitor for renal function, hepatic function, and gastrointestinal bleeding.
Initiate with lowest effective dose, monitor for respiratory depression and constipation; maximum 4 tablets per day in patients >65 years.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion (especially in children); neonatal opioid withdrawal syndrome; risk from concomitant use with benzodiazepines or other CNS depressants; cytochrome P450 2D6 ultra-rapid metabolizers (risk of life-threatening respiratory depression from codeine).
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion (especially in children) can be fatal; neonatal opioid withdrawal syndrome; cytochrome P450 3A4 interaction (concomitant use with CYP3A4 inhibitors may increase hydrocodone levels); risk of medication errors (confusion between different strengths).
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; ultra-rapid metabolism of codeine (CYP2D6); gastrointestinal bleeding (NSAIDs); cardiovascular thrombotic events; renal toxicity; hepatic impairment; elderly patients; pregnancy.
Addiction, abuse, and misuse; respiratory depression; neonatal opioid withdrawal syndrome; interactions with CNS depressants; risk of serotonin syndrome with serotonergic drugs; adrenal insufficiency; hypotension; seizures; gastrointestinal obstruction; severe cutaneous reactions (acetaminophen); hepatotoxicity (acetaminophen overdose); acute abdominal conditions; impaired mental/physical abilities; elderly/debilitated patients; renal/hepatic impairment.
Hypersensitivity to codeine, ibuprofen, or any component; patients with significant respiratory depression; acute or severe bronchial asthma (in an unmonitored setting or without resuscitative equipment); gastrointestinal bleeding; history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; in the setting of coronary artery bypass graft (CABG) surgery; children <12 years old; breastfeeding (ultra-rapid metabolizers of codeine).
Significant respiratory depression; acute or severe bronchial asthma (without monitoring or resuscitative equipment); known or suspected gastrointestinal obstruction (including paralytic ileus); hypersensitivity to hydrocodone or acetaminophen; use with MAOIs or within 14 days of such therapy.
Avoid grapefruit juice as it may increase tramadol levels. High-fat meals may delay absorption but not overall effect. No specific dietary restrictions beyond avoiding alcohol.
Avoid alcohol due to increased risk of acetaminophen hepatotoxicity and additive CNS depression. Grapefruit juice may increase hydrocodone absorption; consider avoiding. No other significant food interactions.
Pregnancy Category D for NSAID component (diclofenac): Avoid in third trimester due to risk of premature ductus arteriosus closure and oligohydramnios. First and second trimester use associated with increased risk of miscarriage and cardiac malformations. Paracetamol component is generally considered low risk but chronic high doses may increase risk of fetal hepatotoxicity.
FDA Category C. First trimester: Possible increased risk of cardiac defects with oxycodone. Second/third trimester: Chronic use may lead to neonatal opioid withdrawal syndrome; no clear teratogenicity. Acetaminophen is generally safe, but high doses may be hepatotoxic.
Diclofenac excreted in breast milk in low amounts (M/P ratio ~0.02-0.05); paracetamol M/P ratio ~1.0. Both considered compatible with breastfeeding at recommended doses. However, avoid if infant has hypersensitivity or G6PD deficiency. Monitor infant for sedation or respiratory depression if used with opioids.
Oxycodone: M/P ratio ~0.8-3; present in milk; risk of neonatal sedation. Acetaminophen: M/P ~0.8-1, low risk. Avoid due to oxycodone; consider alternative analgesic.
Increased renal clearance in pregnancy may reduce plasma levels; however, dose adjustments are not recommended due to fetal safety concerns. Use lowest effective dose for shortest duration. Avoid NSAIDs after 20 weeks gestation; if necessary, reduce dose and limit duration.
Increased clearance of oxycodone in pregnancy may require increased dose; acetaminophen pharmacokinetics unchanged. Adjust based on pain control and withdrawal risk.
Invagesic Forte (paracetamol 500 mg + tramadol 37.5 mg) is a fixed-dose combination analgesic. Tramadol is a prodrug requiring CYP2D6 metabolism; poor metabolizers may have reduced efficacy. Monitor for serotonin syndrome when used with SSRIs, SNRIs, or MAOIs. Maximum daily tramadol dose is 300 mg (8 tablets). Seizure risk increases in patients taking SSRIs, tricyclics, or with epilepsy.
Fixed-dose combination of hydrocodone bitartrate (7.5 mg) and acetaminophen (650 mg). Hydrocodone is a schedule II controlled substance with high abuse potential. Acetaminophen hepatotoxicity risk increases above 3 g/day; prescribe no more than 4 doses per day. Monitor for respiratory depression, especially in opioid-naïve patients. Avoid in severe hepatic impairment. Use with caution in patients with COPD, sleep apnea, or concurrent CNS depressants. Consider naloxone co-prescription if high opioid dose or concurrent benzodiazepine use.
Take exactly as prescribed; do not exceed 8 tablets daily.,May cause dizziness or drowsiness; avoid driving or operating machinery.,Avoid alcohol while taking this medication.,Do not take with other medications containing acetaminophen (paracetamol) to avoid liver damage.,Report severe constipation, nausea, or difficulty breathing to your doctor.,Do not stop abruptly; withdrawal symptoms may occur.
Take exactly as prescribed; do not increase dose or frequency.,Do not take with alcohol or other medications containing acetaminophen.,May cause drowsiness or dizziness; avoid driving or operating machinery until effects are known.,Store securely out of reach of children and others; dispose of unused tablets properly.,Seek emergency care for difficulty breathing, severe sedation, or signs of allergic reaction.,Do not abruptly stop after prolonged use; withdrawal symptoms may occur.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about INVAGESIC FORTE vs ANEXSIA 7.5/650, answered by our medical review team.
INVAGESIC FORTE is a Opioid Analgesic Combination that works by Combination of an opioid agonist (codeine) and a non-opioid analgesic (ibuprofen). Codeine is metabolized to morphine, which binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Ibuprofen inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby decreasing inflammation and pain.. ANEXSIA 7.5/650 is a Opioid Analgesic Combination that works by Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception; acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and fever.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between INVAGESIC FORTE and ANEXSIA 7.5/650 depend on the specific clinical indication. These are both Opioid Analgesic Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of INVAGESIC FORTE is: One tablet (hydrocodone bitartrate 10 mg / acetaminophen 300 mg / ibuprofen 200 mg) orally every 4 to 6 hours as needed for pain; maximum 5 tablets per day.. The standard adult dose of ANEXSIA 7.5/650 is: 1 tablet orally every 4 to 6 hours as needed; maximum 6 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between INVAGESIC FORTE and ANEXSIA 7.5/650 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. INVAGESIC FORTE is classified as Category C. Pregnancy Category D for NSAID component (diclofenac): Avoid in third trimester due to risk of premature ductus arteriosus closure and oligohydramnios. First and second trimester u. ANEXSIA 7.5/650 is classified as Category C. FDA Category C. First trimester: Possible increased risk of cardiac defects with oxycodone. Second/third trimester: Chronic use may lead to neonatal opioid withdrawal syndrome; no . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.